Jack Gagné

Jack Gagné

Auto-generated profile, based on publicly available information

Jack Gagné

NYU Langone Orthopedic Hospital, New York, New York, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2023 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Open access
IMIrini Manoli
Irini Manoli
AGAbigael Gebremariam
Abigael Gebremariam
SMSamantha McCoy
Samantha McCoy
APAlexandra R. Pass
Alexandra R. Pass
JGJack Gagné
Jack Gagné
CVCharles P. Venditti
Charles P. Venditti
Methylmalonic Acidemia (MMA) is a heterogenous group of inborn errors of metabolism caused by a defect in the methylmalonyl‐CoA mutase (MMUT) enzyme or the synthesis and transport of its cofactor, 5′‐deoxy‐adenosylcobalamin. It is characterized by life‐threatening episodes of ketoacidosis, chronic kidney disease, and other multiorgan complications. Liver transplantation can improve patient stability and survival and thus provides clinical and biochemical benchmarks for the development of hepatocyte‐targeted genomic therapies. Data are presented from a US natural history protocol that evaluated subjects with different types of MMA including mut‐type (N = 91), cblB‐type (15), and cblA‐type MMA (17), as well as from an Italian cohort of mut‐type (N = 19) and cblB‐type MMA (N = 2) subjects, including data before and after organ transplantation in both cohorts. Canonical metabolic markers, such as serum methylmalonic acid and propionylcarnitine, are variable and affected by dietary intake and renal function. We have therefore explored the use of the 1‐13C‐propionate oxidation breath test (POBT) to measure metabolic capacity and the changes in circulating proteins to assess mitochondrial dysfunction (fibroblast growth factor 21 [FGF21] and growth differentiation factor 15 [GDF15]) and kidney injury (lipocalin‐2 [LCN2]). Biomarker concentrations are higher in patients with the severe mut0‐type and cblB‐type MMA, correlate with a decreased POBT, and show a significant response postliver transplant. Additional circulating and imaging markers to assess disease burden are necessary to monitor disease progression. A combination of biomarkers reflecting disease severity and multisystem involvement will be needed to help stratify patients for clinical trials and assess the efficacy of new therapies for MMA.

9 June 2025 in Orthopaedic Journal of Sports Medicine
Verified
Journal Article
Open access
JGJack Gagné
Jack Gagné
MLMichael S. Lee
Michael S. Lee
SPSeema M. Patel
Seema M. Patel
TKTrevan Klug
Trevan Klug
PMPeter F. Monahan
Peter F. Monahan
AJAndrew E. Jimenez
Andrew E. Jimenez
Background: Hip labral and chondral lesions are commonly found as co-occurring conditions in patients with abductor tendon tears. Concomitant hip arthroscopic surgery for the correction of intra-articular abnormalities and endoscopic abductor tendon repair has therefore emerged as a strategy to address these conditions simultaneously. Purpose: To systematically review the existing literature assessing clinical outcomes after endoscopic abductor tendon repair with concomitant hip arthroscopic surgery for the treatment of intra-articular abnormalities. Study Design: Systematic review; Level of evidence, 4. Methods: Under PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, the PubMed, CENTRAL, and Scopus databases were queried in May 2023 to conduct this systematic review using the keywords “hip arthroscopy,”“gluteal,”“abductor,”“gluteus,”“minimus,” and “medius.” Articles were included if they reported preoperative and postoperative patient-reported outcome measure (PROM) scores for patients undergoing endoscopic abductor tendon repair for gluteus medius and/or gluteus minimus tears with concomitant hip arthroscopic surgery for the treatment of labral tears and/or femoroacetabular impingement. We identified a total of 404 articles after our initial search. Title, author, publication date, study design, patient characteristics, preoperative radiographic findings (lateral center-edge angle, alpha angle, and Tönnis grade), concomitant surgical procedures performed, preoperative and postoperative PROM scores, measures of clinical benefit, and secondary surgery performed (revision arthroscopic surgery, revision abductor tendon repair, and conversion to total hip arthroplasty) were recorded. P values were extracted from the articles included in our review, all of which defined statistical significance as P < .05. We were unable to create forest plots for these data, given that no single PROM (preoperative and postoperative scores in means and standard deviations) was reported in ≥3 articles. This also prevented us from further analyzing heterogeneity. We calculated the total rate of secondary surgical procedures by dividing the instances of these events by the total number of patients across the 4 studies that included these outcome measures. Results: After duplicate articles were removed, 270 articles entered the abstract screening phase, and 11 full-text articles were reviewed. Overall, 5 articles were included in the systematic review. A total of 223 hips were included, with mean follow-up times ranging from 26 to 74 months. All studies reported a significant improvement ( P < .05) on all reported PROMs from preoperative to latest postoperative time points. There were 2 studies that compared combined endoscopic abductor tendon repair and labral treatment with a matched group undergoing hip arthroscopic surgery alone and found no significant differences ( P > .05) between groups. Among studies reporting secondary surgical procedures, there was 1 case (0.9%) of revision abductor tendon repair and 5 cases (4.3%) of conversion to total hip arthroplasty. Conclusion: Our systematic review demonstrated that patients who underwent concomitant endoscopic abductor tendon repair and hip arthroscopic surgery had significant improvements on PROMs with low rates of secondary surgery at a minimum 2-year follow-up. Longer-term studies are needed for us to understand concomitant treatment methods for multiple abnormalities in patients undergoing hip arthroscopic surgery in the future.